Acer Therapeutics Inc. ACER Income Statement

Acer therapeutics inc. (ACER)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Sep'10	Jun'10
Operating expenses:
Option Revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,905	2,905	2,556	2,137	1,719	1,300	1,271	1,313	1,354	1,395	1,266	0	0	0	-	-	-	-	-	-	-	-	-	-
Research and development
12,227	13,851	16,333	15,882	14,324	12,452	8,916	8,595	7,765	8,725	10,224	6,556	6,513	5,308	4,595	8,626	9,231	10,039	10,202	10,955	11,944	12,118	12,236	11,557	10,370	9,181	8,153	7,114	6,449	6,318	5,650	4,848	4,144	3,340	2,819	2,949	0	0	0
General and administrative
14,464	16,046	17,070	16,266	11,575	9,261	8,305	7,878	6,806	5,223	2,517	940	737	1,391	2,870	4,168	4,239	4,258	3,899	3,793	3,736	3,833	4,178	3,887	3,671	3,670	3,110	3,015	2,794	2,508	2,546	2,599	2,630	2,406	2,364	2,375	0	0	0
Total operating expenses
26,691	29,897	33,404	32,149	25,899	21,713	17,221	16,473	14,572	13,948	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss from operations
-26,691	-29,897	-33,404	-32,149	-25,899	-21,713	-17,221	-16,473	-14,572	-13,948	-14,055	-8,810	-7,904	-6,699	-5,500	-10,193	-10,893	-12,093	-12,337	-13,410	-14,769	-15,067	-15,472	-14,455	-13,001	-11,923	-10,684	-9,891	-9,342	-9,133	-8,484	-7,711	-7,033	-5,966	-5,379	-5,511	0	0	0
Other income, net:
Interest income (expense), net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	5	5	7	9	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest income
311	471	626	674	567	412	216	80	45	14	0	0	0	-	0	-	-	-	-	-	-	-	-	-	18	14	9	5	2	0	0	0	0	0	1	1	0	0	0
Loss on extinguishment of debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Gain on derivative instruments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Interest expense
-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	-	-	-	-	-	-	-	-	-	-	2,267	2,465	2,270	1,985	350	152	2	2	3	4	396	0	0	0
Loss on disposal of asset
-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Foreign currency transaction (loss) gain
-17	8	19	3	66	20	7	4	-39	-16	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total other income, net
0	-	0	-	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation and amortization
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	303	327	351	371	379	389	387	369	362	352	335	336	327	314	303	278	253	247	210	194	186	0	0	0
Loss on disposal of asset
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	0	-	-	0	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Total other income, net
-	-	-	676	-	-	-	-37	-226	-246	-243	-125	-14	0	39	50	59	68	36	24	13	2	0	0	0	37	0	0	0	-	-	-	-	-	-	-	-	-	-
Net loss
-26,397	-29,417	-32,757	-31,472	-25,265	-21,280	-16,998	-16,511	-14,798	-14,194	-10,529	-8,936	-7,918	-6,699	-9,230	-10,139	-10,828	-12,019	-12,294	-13,378	-14,747	-15,052	-15,455	-17,301	-16,134	-16,656	-14,932	-11,566	-10,734	-8,930	-8,773	-7,712	-7,034	-5,968	-5,382	-5,905	0	0	0
Net loss per share - basic and diluted
-0.49	-0.51	-0.52	-1.09	-0.79	-0.89	-0.43	-0.64	-0.53	-0.08	-1.09	-1.29	-1.38	-1.35	-0.77	-0.30	-0.31	-0.26	-0.42	-0.42	-0.95	-2.94	-1.11	-0.15	-0.13	0.09	-0.39	-0.37	-0.58	-0.35	-0.40	-0.38	-0.41	-0.88	-0.06	-0.06	-0.06	-0.07	-0.12
Weighted average common shares outstanding - basic and diluted
10,097	10,095	10,095	10,090	10,087	10,088	9,136	7,497	7,497	6,704	3,199	2,423	2,450	-6,628	2,450	6,995	6,982	6,469	6,709	6,709	3,529	-44,814	3,478	27,661	27,584	23,377	14,721	7,991	7,239	5,855	5,762	5,762	5,762	-	23,048	23,048	-	-	-
Weighted average shares outstanding
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	20,955	18,421	15,827